Inhibition of Ras attenuates the course of experimental autoimmune neuritis

Michal Kafri; Yoel Kloog; Amos D. Korczyn; Ramona Ferdman-Aronovich; Vivian Drory; Aviva Katzav; Itzhak Wirguin; Joab Chapman

doi:10.1016/j.jneuroim.2005.07.008

Inhibition of Ras attenuates the course of experimental autoimmune neuritis

Michal Kafri, Yoel Kloog, Amos D. Korczyn, Ramona Ferdman-Aronovich, Vivian Drory, Aviva Katzav, Itzhak Wirguin, Joab Chapman

Research output: Contribution to journal › Article › peer-review

Abstract

EAN induced in Lewis rats by immunization with peripheral bovine myelin was treated by the Ras inhibitor farnesylthiosalicylate (FTS). Treatment from day 0 with FTS (5 mg/kg intraperitoneally twice daily) attenuated peak clinical scores (mean ± S.E., 2.5 ± 0.5 compared to 4.1 ± 0.5 in saline treated controls, p = 0.018, t-test) but not recovery. Treatment from day 10 with FTS attenuated peak disability (2.5 ± 0.6, p = 0.032 compared to saline treated controls) and improved recovery (0.84 ± 0.42, untreated controls 2.4 ± 0.6, p = 0.028 by repeated measures ANOVA). Effects were confirmed by rotarod and nerve conduction studies. An inactive analogue, geranylthiosalicylate, had no clinical effect. Inhibition of Ras is of potential use in the treatment of inflammatory neuropathies.

Original language	English
Pages (from-to)	46-55
Number of pages	10
Journal	Journal of Neuroimmunology
Volume	168
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2005.07.008
State	Published - Nov 2005
Externally published	Yes

Bibliographical note

Funding Information:
This study was supported by the Bircher–Benner Fund founded by Dr. Abraham Avrech, the Sieratzki Chair of Neurology, Tel Aviv University and Thyreos Inc, Newark, NJ, USA.

Keywords

Experimental autoimmune neuritis
Farnesylthiosalicylate
Guillain-Barré syndrome
Nerve conduction
Ras
Rat

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jneuroim.2005.07.008

Cite this

@article{d252bdfd87104681922fcbed8c8278c4,

title = "Inhibition of Ras attenuates the course of experimental autoimmune neuritis",

abstract = "EAN induced in Lewis rats by immunization with peripheral bovine myelin was treated by the Ras inhibitor farnesylthiosalicylate (FTS). Treatment from day 0 with FTS (5 mg/kg intraperitoneally twice daily) attenuated peak clinical scores (mean ± S.E., 2.5 ± 0.5 compared to 4.1 ± 0.5 in saline treated controls, p = 0.018, t-test) but not recovery. Treatment from day 10 with FTS attenuated peak disability (2.5 ± 0.6, p = 0.032 compared to saline treated controls) and improved recovery (0.84 ± 0.42, untreated controls 2.4 ± 0.6, p = 0.028 by repeated measures ANOVA). Effects were confirmed by rotarod and nerve conduction studies. An inactive analogue, geranylthiosalicylate, had no clinical effect. Inhibition of Ras is of potential use in the treatment of inflammatory neuropathies.",

keywords = "Experimental autoimmune neuritis, Farnesylthiosalicylate, Guillain-Barr{\'e} syndrome, Nerve conduction, Ras, Rat",

author = "Michal Kafri and Yoel Kloog and Korczyn, {Amos D.} and Ramona Ferdman-Aronovich and Vivian Drory and Aviva Katzav and Itzhak Wirguin and Joab Chapman",

note = "Funding Information: This study was supported by the Bircher–Benner Fund founded by Dr. Abraham Avrech, the Sieratzki Chair of Neurology, Tel Aviv University and Thyreos Inc, Newark, NJ, USA.",

year = "2005",

month = nov,

doi = "10.1016/j.jneuroim.2005.07.008",

language = "English",

volume = "168",

pages = "46--55",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Inhibition of Ras attenuates the course of experimental autoimmune neuritis

AU - Kafri, Michal

AU - Kloog, Yoel

AU - Korczyn, Amos D.

AU - Ferdman-Aronovich, Ramona

AU - Drory, Vivian

AU - Katzav, Aviva

AU - Wirguin, Itzhak

AU - Chapman, Joab

N1 - Funding Information: This study was supported by the Bircher–Benner Fund founded by Dr. Abraham Avrech, the Sieratzki Chair of Neurology, Tel Aviv University and Thyreos Inc, Newark, NJ, USA.

PY - 2005/11

Y1 - 2005/11

N2 - EAN induced in Lewis rats by immunization with peripheral bovine myelin was treated by the Ras inhibitor farnesylthiosalicylate (FTS). Treatment from day 0 with FTS (5 mg/kg intraperitoneally twice daily) attenuated peak clinical scores (mean ± S.E., 2.5 ± 0.5 compared to 4.1 ± 0.5 in saline treated controls, p = 0.018, t-test) but not recovery. Treatment from day 10 with FTS attenuated peak disability (2.5 ± 0.6, p = 0.032 compared to saline treated controls) and improved recovery (0.84 ± 0.42, untreated controls 2.4 ± 0.6, p = 0.028 by repeated measures ANOVA). Effects were confirmed by rotarod and nerve conduction studies. An inactive analogue, geranylthiosalicylate, had no clinical effect. Inhibition of Ras is of potential use in the treatment of inflammatory neuropathies.

AB - EAN induced in Lewis rats by immunization with peripheral bovine myelin was treated by the Ras inhibitor farnesylthiosalicylate (FTS). Treatment from day 0 with FTS (5 mg/kg intraperitoneally twice daily) attenuated peak clinical scores (mean ± S.E., 2.5 ± 0.5 compared to 4.1 ± 0.5 in saline treated controls, p = 0.018, t-test) but not recovery. Treatment from day 10 with FTS attenuated peak disability (2.5 ± 0.6, p = 0.032 compared to saline treated controls) and improved recovery (0.84 ± 0.42, untreated controls 2.4 ± 0.6, p = 0.028 by repeated measures ANOVA). Effects were confirmed by rotarod and nerve conduction studies. An inactive analogue, geranylthiosalicylate, had no clinical effect. Inhibition of Ras is of potential use in the treatment of inflammatory neuropathies.

KW - Experimental autoimmune neuritis

KW - Farnesylthiosalicylate

KW - Guillain-Barré syndrome

KW - Nerve conduction

KW - Ras

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=25844440047&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2005.07.008

DO - 10.1016/j.jneuroim.2005.07.008

M3 - Article

C2 - 16154640

AN - SCOPUS:25844440047

SN - 0165-5728

VL - 168

SP - 46

EP - 55

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

Inhibition of Ras attenuates the course of experimental autoimmune neuritis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this